Cystatin C: A potential biomarker for pulmonary arterial hypertension

Respirology

Volumn 19, Issue 4, 2014, Pages 583-589

  Fenster, Brett E ^a   Lasalvia, Luis ^b   Schroeder, Joyce D ^a   Smyser, Jamey ^a   Silveira, Lori J ^a   Buckner, J Kern ^a   Brown, Kevin K ^a  

^a DEPARTMENT OF MEDICINE   (United States)

^b Siemens Healthcare Diagnostics Inc   (United States)

Author keywords

brain natriuretic peptide; cystatin C; echocardiography; pulmonary arterial hypertension; right ventricle

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; BIOLOGICAL MARKER; BRAIN NATRIURETIC PEPTIDE; CYSTATIN C; SILDENAFIL; TADALAFIL; PEPTIDE FRAGMENT; PRO-BRAIN NATRIURETIC PEPTIDE (1-76);

ADULT; AGED; ARTICLE; BLOOD FLOW VELOCITY; CARDIOVASCULAR MAGNETIC RESONANCE; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DIASTOLIC BLOOD PRESSURE; DOPPLER ECHOCARDIOGRAPHY; HEART FUNCTION; HEART INDEX; HEART RIGHT VENTRICLE; HEART RIGHT VENTRICLE EJECTION FRACTION; HEART RIGHT VENTRICLE ENDDIASTOLIC VOLUME; HEART RIGHT VENTRICLE ENDSYSTOLIC VOLUME; HEART RIGHT VENTRICLE PRESSURE; HEART RIGHT VENTRICLE VOLUME; HUMAN; MIDDLE AGED; NUCLEAR MAGNETIC RESONANCE SCANNER; PHLEBOTOMY; PREDICTIVE VALUE; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; PULMONARY HYPERTENSION; RIGHT VENTRICULAR SYSTOLIC PRESSURE; SERUM; SYSTOLIC BLOOD PRESSURE; TRICUSPID VALVE; TWO DIMENSIONAL ECHOCARDIOGRAPHY; BLOOD; FEMALE; HEART RIGHT VENTRICLE FUNCTION; HEART STROKE VOLUME; HYPERTENSION, PULMONARY; LUNG CIRCULATION; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOPHYSIOLOGY; PILOT STUDY; REPRODUCIBILITY; STATISTICS;

BIOLOGICAL MARKERS; CYSTATIN C; FEMALE; HUMANS; HYPERTENSION, PULMONARY; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; NATRIURETIC PEPTIDE, BRAIN; PEPTIDE FRAGMENTS; PILOT PROJECTS; PULMONARY CIRCULATION; REPRODUCIBILITY OF RESULTS; STATISTICS AS TOPIC; STROKE VOLUME; VENTRICULAR FUNCTION, RIGHT;

EID: 84899123702     PISSN: 13237799     EISSN: 14401843     Source Type: Journal    
DOI: 10.1111/resp.12259     Document Type: Article

References (36)

1. Benza RL, Miller DP, Gomberg-Maitland M, Frantz RP, Foreman AJ, Coffey CS, Frost A, Barst RJ, Badesch DB, Elliott CG, et al. Predicting survival in pulmonary arterial hypertension: insights from the Registry to Evaluate Early and Long-Term Pulmonary Arterial Hypertension Disease Management (REVEAL). Circulation 2010; 122: 164-172.
2. Chin KM, Kim NH, Rubin LJ,. The right ventricle in pulmonary hypertension. Coron. Artery Dis. 2005; 16: 13-18.
3. D'Alonzo GE, Barst RJ, Ayres SM, Bergofsky EH, Detre KM, Fishman AP, Goldring RM, Groves RM, Groves BM, Kernis JT, et al. Survival in patients with primary pulmonary hypertension. Results from a national prospective registry. Ann. Intern. Med. 1991; 5: 343-349.
4. McLaughlin VV, Presberg KW, Doyle RL, Abman SH, McCrory DC, Fortin T, Ahearn G,. Prognosis of pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines. Chest 2004; 126: 78S-92S.
5. van Wolferen SA, Marcus JT, Boonstra A, Marques KM, Bronzwaer JG, Spreeuwenberg MD, Postmus PE, Vonk-Noordegraaf A,. Prognostic value of right ventricular mass, volume, and function in idiopathic pulmonary arterial hypertension. Eur. Heart J. 2007; 28: 1250-1257.
6. Leuchte HH, Holzapfel M, Baumgartner RA, Ding I, Neurohr C, Vogeser M, Kolbe T, Schwaiblmair M, Behr J,. Clinical significance of brain natriuretic peptide in primary pulmonary hypertension. J. Am. Coll. Cardiol. 2004; 43: 764-770.
7. Batal O, Faulx M, Krasuski RA, Khatib OF, Hammel JP, Hussein AA, Minai OA, Dweik RA,. Effect of obesity on B-type natriuretic peptide levels in patients with pulmonary arterial hypertension. Am. J. Cardiol. 2012; 110: 909-914.
8. Rivera M, Cortés R, Salvador A, Bertomeu V, de Burgos FG, Paya R, Portoles M, Talens-Visconti R, Martinez-Dolz L, Valero R, et al. Obese subjects with heart failure have lower N-terminal pro brain natriuretic peptide plasma levels irrespective of aetiology. Eur. J. Heart Fail. 2005; 7: 1168-1170.
9. Mehra MR, Uber PA, Park MH, Scott RL, Ventura HO, Harris BC, Frohlich ED,. Obesity and suppressed B-type natriuretic peptide levels in heart failure. J. Am. Coll. Cardiol. 2004; 43: 1590-1595.
10. Raymond I, Groenning BA, Hildebrandt PR, Nilsson JC, Baumann M, Trawinski J, Pedersen F,. The influence of age, sex and other variables on the plasma level of N-terminal pro brain natriuretic peptide in a large sample of the general population. Heart 2003; 89: 745-751.
11. Redfield MM, Rodeheffer RJ, Jacobsen SJ, Mahoney DW, Bailey KR, Burnett JC Jr,. Plasma brain natriuretic peptide concentration: impact of age and gender. J. Am. Coll. Cardiol. 2002; 40: 976-982.
12. Wang TJ, Larson MG, Levy D, Leip EP, Benjamin EJ, Wilson PW, Sutherland P, Omland T, Vasan RS,. Impact of age and sex on plasma natriuretic peptide levels in healthy adults. Am. J. Cardiol. 2002; 90: 254-258.
13. Fliser D, Ritz E,. Serum cystatin C concentration as a marker of renal dysfunction in the elderly. Am. J. Kidney Dis. 2001; 37: 79-83.
14. Dharnidharka VR, Kwon C, Stevens G,. Serum cystatin C is superior to serum creatinine as a marker of kidney function: a meta-analysis. Am. J. Kidney Dis. 2002; 40: 221-226.
15. Shlipak MG, Katz R, Fried LF, Jenny NS, Stehman-Breen C, Newman AB, Siscovick D, Psaty BM, Sarnak MJ,. Cystatin-C and mortality in elderly persons with heart failure. J. Am. Coll. Cardiol. 2005; 45: 268-271.
16. Ix JH, Shlipak MG, Chertow GM, Whooley MA,. Association of cystatin C with mortality, cardiovascular events, and incident heart failure among persons with coronary heart disease: data from the Heart and Soul Study. Circulation 2007; 115: 173-179.
17. Lassus J, Harjola VP, Sund R, Siirila-Waris K, Melin J, Peuhkurinen K, Pulkki K, Niemenin MS, FINN-AKVA Study Group. Prognostic value of cystatin C in acute heart failure in relation to other markers of renal function and NT-proBNP. Eur. Heart J. 2007; 28: 1841-1847.
18. Pérez-Calvo JI, Ruiz-Ruiz FJ, Carrasco-Sánchez FJ, Morales-Rull JL, Manzano-Fernández S, Galisteo-Almeda L, Pascual-Figal D,. Prognostic value of serum cystatin C and N-terminal pro b-type natriuretic peptide in patients with acute heart failure. Eur. J. Intern. Med. 2012; 7: 599-603.
19. Coll E, Botey A, Alvarez L, Poch E, Quintõ L, Saurina A, Vera M, Piera C, Darnell A,. Serum cystatin C as a new marker for noninvasive estimation of glomerular filtration rate and as a marker for early renal impairment. Am. J. Kidney Dis. 2000; 36: 29-34.
20. Tang WH, Van Lente F, Shrestha K, Troughton RW, Francis GS, Tong W, Martin MG, Borowski AG, Jasper S, Starling RC, et al. Impact of myocardial function on cystatin c measurements in chronic systolic heart failure. J. Card. Fail. 2008; 14: 394-399.
21. Eysmann SB, Palevsky HI, Reichek N, Hackney K, Douglas PS,. Two dimensional and Doppler-echocardiographic and cardiac catheterization correlates of survival in primary pulmonary hypertension. Circulation 1989; 80: 353-360.
22. Utsunomiya H, Nakatani S, Nishihira M, Kanzaki H, Kyotani S, Nakanishi N, Kihara Y, Kitakaze M,. Value of estimated right ventricular filling pressure in predicting cardiac events in chronic pulmonary arterial hypertension. J. Am. Soc. Echocardiogr. 2009; 12: 1368-1374.
23. Hardegree EL, Sachdev A, Villarraga HR, Frantz RP, McGoon MD, Kushwaha SS, Hsiao JF, McCully RB, Oh JK, Pellikka PA, et al. Role of serial quantitative assessment of right ventricular function by strain in pulmonary arterial hypertension. Am. J. Cardiol. 2013; 111: 143-148.
24. McLaughlin VV, Archer SL, Badesch DB, Barst RJ, Farber HW, Lindner JR, Mathier MA, McGoon MD, Park MH, Rosenson RS, et al. ACCF/AHA. ACCF/AHA.ACCF/AHA 2009 expert consensus document on pulmonary hypertension: a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association: developed in collaboration with the American College of Chest Physicians, American Thoracic Society, Inc., and the Pulmonary Hypertension Association. Circulation 2009; 119: 2250-2294.
25. Rudski LG, Lai WW, Afilalo J, Hua L, Handschumacher MD, Chandrasekaran K, Solomon SD, Louie EK, Schiller NB,. Guidelines for the echocardiographic assessment of the right heart in adults: a report from the American Society of Echocardiography endorsed by the European Association of Echocardiography, a registered branch of the European Society of Cardiology, and the Canadian Society of Echocardiography. J. Am. Soc. Echocardiogr. 2010; 23: 685-713.
26. Yock PG, Popp RL,. Noninvasive estimation of right ventricular systolic pressure by Doppler ultrasound in patients with tricuspid regurgitation. Circulation 1984; 70: 657-662.
27. Kaul S, Tei C, Hopkins JM, Shah PM,. Assessment of right ventricular function using two-dimensional echocardiography. Am. Heart J. 1984; 107: 526-531.
28. Rojo EC, Rodrigo JL, Perez de Isla L, Almería C, Gonzalo N, Aubele A, Cinza R, Zamorano J, Macaya C,. Disagreement between tissue Doppler imaging and conventional pulsed wave Doppler in the measurement of myocardial performance index. Eur. J. Echocardiogr. 2006; 356-364.
29. Pirat B, McCulloch ML, Zoghbi WA,. Evaluation of global and regional right ventricular systolic function in patients with pulmonary hypertension using a novel speckle tracking method. Am. J. Cardiol. 2006; 98: 699-704.
30. Lorenz CH, Walker ES, Morgan VL, Klein SS, Graham TP Jr,. Normal human right and left ventricular mass, systolic function, and gender differences by cine magnetic resonance imaging. J. Cardiovasc. Magn. Reson. 1999; 1: 7-21.
31. Levey AS, Coresh J, Greene T, Stevens LA, Zhang YL, Hendriksen S, Kusek JW, Van Lente F, Chronic Kidney Disease Epidemiology Collaboration. Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate. Ann. Intern. Med. 2006; 145: 247-254.
32. Mielniczuk LM, Chandy G, Stewart D, Contreras-Dominguez V, Haddad H, Pugliese C, Davies RA,. Worsening renal function and prognosis in pulmonary hypertension patients hospitalized for right heart failure. Congest. Heart Fail. 2012; 18: 151-157.
33. Patel PC, Ayers CR, Murphy SA,. Association of cystatin c with left ventricular structure and function: the Dallas heart study. Circ. Heart Fail. 2009; 2: 98-104.
34. Cheng XW, Obata K, Kuzuya M, Izawa H, Nakamura K, Asai E, Nagasaka T, Saka M, Kimata T, Noda A, et al. Elastolytic cathepsin induction/activation system exists in myocardium and is upregulated in hypertensive heart failure. Hypertension 2006; 5: 979-987.
35. Fisher MR, Forfia PR, Chamera E, Housten-Harris T, Champion HC, Girgis RE, Corretti MC, Hassoun PM,. Accuracy of Doppler echocardiography in the hemodynamic assessment of pulmonary hypertension. Am. J. Respir. Crit. Care Med. 2009; 179: 615-621.
36. Manetti L, Pardini E, Genovesi M, Campomori A, Grasso L, Morselli LL, Lupi I, Pellegrini G, Bartalena L, Bogazzi F, et al. Thyroid function differently affects serum cystatin C and creatinine concentrations. J. Endocrinol. Invest. 2005; 28: 346-349.